Business Context and Reporting Period
This Form 8-K was filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on October 7, 2022, reporting an event that occurred on October 4, 2022. The registrant is a Delaware corporation trading on the Nasdaq Capital Market under the symbol AIKI.
Key Financial Metrics
This filing is a Current Report regarding a corporate event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material change reported is a strategic acquisition:
- Acquisition: Dominari Financial Inc., a wholly owned subsidiary of Aikido Pharma Inc., completed the purchase of 20% of the membership interests in Fieldpoint Private Securities, LLC.
- Target Profile: Fieldpoint Private Securities, LLC is a broker-dealer registered with the Financial Industry Regulatory Authority (FINRA).
- Transaction Status: This represents the first closing. The second and final closing for the remaining membership interest is contingent upon final approval from FINRA.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary contingency noted is the requirement for final FINRA approval to complete the acquisition of the remaining membership interest in Fieldpoint Private Securities, LLC.
Investor Verification Checklist
- Verify the regulatory status of Fieldpoint Private Securities, LLC with FINRA.
- Monitor for the filing of the second closing event once FINRA approval is granted.
- Review the full Membership Interest Purchase Agreement (Exhibit 2.1) referenced in the September 9, 2022 Form 8-K for complete terms.
- Confirm the strategic rationale for a pharmaceutical company (Aikido Pharma) acquiring a stake in a broker-dealer.